Helix BioPharma Corp., an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, has appointed paediatric surgeon Dr. Krzysztof Saczek to its board of directors.
As a paediatric surgeon, Dr. Saczek is experienced in treating solid tumors, including malignancies in children. He has trained and practiced in several prominent medical centers in North America, Europe, and South Africa. His area of expertise includes gastrointestinal oncology.
READ: Helix BioPharma plans management shakeup in September
Dr. Saczek's professional designations include being a member of the Saskatchewan Medical Association and the CPSS (College of Physicians and Surgeons of Saskatchewan). Currently, he is the head of the Paediatric Surgery Department at the Regina General Hospital in Regina, Saskatchewan.
"Dr. Saczek brings a wealth of experience to the Company and we look forward to having the opportunity to work with him in further developing the Company's immunotherapy treatments strategy going forward," said Helix BioPharma Board Chairman Sławomir Majewski in a statement.
Helix BioPharma’s DOS47 is designed to turn a tumor's environment to alkaline from acid, which, in turn, corrects an impaired immune system. The company says it is the only therapeutic in advanced development based on a unique mechanism of action and can be combined with chemotherapy, biologics, and other novel treatments.
Contact the author: patrick@proactiveinvestors.com
Follow him on Twitter @PatrickMGraham